BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang Sells 472 Shares

BeiGene, Ltd. (NASDAQ:BGNE) CFO Julia Aijun Wang sold 472 shares of BeiGene stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $143.90, for a total value of $67,920.80. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Julia Aijun Wang also recently made the following trade(s):

• On Monday, June 24th, Julia Aijun Wang sold 899 shares of BeiGene stock. The stock was sold at an average price of $155.66, for a total value of $139,938.34.

BeiGene Stock Performance

BGNE stock opened at $147.98 on Friday. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $225.23. The company has a quick ratio of 1.84, a current ratio of 2.08 and a debt-to-equity ratio of 0.06. The company has a market cap of $14.28 billion, a P/E ratio of -19.55 and a beta of 0.59. The business’s fifty day moving average is $157.37 and its 200-day moving average is $158.83.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, beating the consensus estimate of ($3.07) by $0.66. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The firm had revenue of $751.70 million for the quarter, compared to analyst estimates of $670.09 million. During the same quarter in the prior year, the firm posted ($3.34) earnings per share. The company’s quarterly revenue was up 67.9% on a year-over-year basis. Equities research analysts forecast that BeiGene, Ltd. will post -8.2 EPS for the current year.

Institutional Investors Weigh In On BeiGene

Large investors have recently bought and sold shares of the company. Capital International Investors increased its position in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after buying an additional 727,556 shares in the last quarter. First Trust Advisors LP acquired a new position in BeiGene in the fourth quarter valued at about $39,632,000. M&G Plc bought a new stake in shares of BeiGene in the first quarter worth about $29,649,000. Goldman Sachs Group Inc. raised its position in shares of BeiGene by 175.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock worth $38,658,000 after purchasing an additional 136,458 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after purchasing an additional 117,905 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BGNE. JPMorgan Chase & Co. raised their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. TD Cowen increased their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Sanford C. Bernstein cut their target price on shares of BeiGene from $196.00 to $161.00 and set a “market perform” rating for the company in a research note on Wednesday, March 27th. Finally, Bank of America reduced their price target on shares of BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $251.93.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.